Prediction: This Space Stock Will Outperform SpaceX Over the Next 10 Years

Rocket Lab's revenue has risen roughly 870% since its 2021 public listing, with a $2.36 billion backlog versus $769 million in trailing revenue, supported by launch and space-systems businesses. The article argues Rocket Lab could reach $10 billion in revenue over the next decade through the Neutron rocket and a planned Iridium Communications acquisition, while trading at 56x sales versus SpaceX at 94x. However, it concludes Rocket Lab is unattractive at its current $44 billion market capitalization because anticipated dilution and potentially low space-industry margins could leave the shares effectively flat even if revenue reaches $10 billion.

Analysis

RKLB’s valuation leaves little room for the normal execution slippage inherent in launch certification, production ramping, and government procurement. The key issue is not revenue growth but conversion into gross margin and free cash flow: moving into medium-lift launch and satellite connectivity increases capital intensity, working-capital needs, and exposure to fixed-cost underabsorption. SpaceX’s scale and vertical integration can sustain aggressive launch pricing, limiting RKLB’s ability to earn attractive returns on Neutron even if demand is robust.

A satellite-connectivity expansion would be strategically double-edged. It could add recurring revenue and reduce dependence on lumpy government awards, but it would also require spectrum, network capex, customer-retention spending, and regulatory approvals while potentially making RKLB a competitor to existing space-systems customers. The claimed IRDM transaction is sufficiently material that terms, financing, regulatory path, and IRDM customer-contract implications must be independently verified before underwriting any synergy value.

Over the next 1-3 months, the stock remains vulnerable to financing/dilution disclosures, Neutron schedule movement, and any evidence that backlog conversion is slower or lower-margin than implied by headline backlog. Over 6-18 months, the decisive KPI set is Neutron test cadence, contracted launch economics, space-systems gross-margin progression, and cash burn per incremental dollar of revenue. Consensus appears to focus on a large addressable market; the underappreciated risk is that launch becomes a structurally low-return service while connectivity requires a much larger balance sheet than RKLB currently has.

The contrarian bull case is that a successful Neutron milestone could force a sharp rerating before meaningful revenue arrives, particularly if investors view it as the only credible public alternative to SpaceX. That outcome requires schedule credibility and non-dilutive funding; absent both, multiple compression can overwhelm operational growth.

Key Decisions for Investors

• Do not initiate unhedged RKLB longs at current valuation; require confirmation of Neutron schedule, funding runway, and at least two quarters of improving consolidated gross margin before upgrading from watchlist status.
• For existing RKLB exposure, buy 6-12 month downside puts or use a collar around major Neutron test/certification milestones; the relevant risk is a discrete schedule or capital-raise shock rather than gradual earnings drift.
• Consider a tactical short RKLB versus long XAR only after a confirmed dilutive financing or launch-delay disclosure; this isolates RKLB-specific valuation risk while reducing broad defense/space-beta exposure. Cover if Neutron reaches a major test milestone on schedule or if backlog converts at materially higher margins.
• Treat IRDM as an event-driven watch item, not an acquisition-arbitrage position, until definitive transaction consideration, financing terms, and regulatory conditions are verified. A cash-heavy premium with credible closing certainty would favor IRDM; stock consideration or extended approval risk would weaken the setup.
• Set falsification alerts: a sustained reduction in quarterly cash burn, improving space-systems margins, and contracted Neutron launches with disclosed economics would challenge the bearish valuation thesis; another material schedule slip or equity issuance would reinforce it.